Contact sports athletes often endure repetitive head impacts alongside significant musculoskeletal injuries throughout their competitive careers. While long-term neurodegenerative conditions such as chronic traumatic encephalopathy remain a central concern, clinicians increasingly recognize the complex intersection between polypharmacy, chronic pain, and behavioral symptoms. Recent research highlights that centrally acting medications and persistent nociceptive inputs contribute substantially to clinical presentations that mimic or exacerbate neurodegenerative syndromes. Consequently, evaluating retired collision athletes requires an expansive approach that accounts for systemic physical health and pharmacotherapy.

Investigators examined whether non-neurological burdens, including surgical interventions, bodily pain, and centrally active drug regimens, directly correlate with cognitive impairment and behavioral dysfunction. By utilizing comprehensive diagnostic criteria from the DIAGNOSE CTE research cohort, the study establishes critical insights into secondary contributors to neuropsychiatric impairment. Therefore, healthcare providers must differentiate underlying tau-mediated pathology from the confounding effects of polypharmacy and intractable pain. Understanding these overlapping drivers enables clinicians to refine diagnostic precision and deliver targeted, multi-modal interventions.

Centrally Acting Medications and Pain Burden in Contact Sports

Former competitive athletes frequently experience severe post-traumatic osteoarthritis, spinal degenerative disorders, and systemic musculoskeletal trauma resulting from years of high-velocity impacts. Consequently, clinicians frequently prescribe centrally acting medications, including prescription opioids, muscle relaxants, anticonvulsants, sedatives, and psychotropic drugs, to manage refractory somatic symptoms. In the analyzed cohort of former professional and collegiate football players, medication use was markedly elevated compared to unexposed controls. Specifically, collegiate players reported an average of 1.14 centrally active drugs, while professional athletes averaged 0.76, contrasting sharply with 0.14 among unexposed men.

Furthermore, daily pain intensity mirrored this pharmacological disparity across the study groups. Professional athletes documented a mean pain score of 4.22 on standardized numeric rating scales, whereas unexposed controls averaged a baseline of 1.05. Although pain medications aim to restore daily functioning, chronic central nervous system exposure can alter neurotransmitter dynamics, disrupt sleep architecture, and induce daytime lethargy. Thus, the physiological burden of unmanaged nociception combined with continuous pharmacological exposure creates a vulnerable neurological environment. Clinicians must recognize that managing chronic pain through central agents without regular reassessment can inadvertently exacerbate cognitive and emotional fragility.

Neurobehavioral Dysregulation and Clinical Outcomes

The primary finding of the study reveals a powerful statistical link between drug exposure, pain intensity, and consensus-diagnosed neurobehavioral dysregulation. Specifically, each additional centrally acting medication more than doubled the odds of formal neurobehavioral dysregulation, yielding an odds ratio of 2.15. Similarly, each one-point increase in average pain scores escalated the odds of neurobehavioral dysregulation by 55 percent. These associations persisted even after rigorously controlling for age, racial background, educational attainment, and total years of active play.

Moreover, linear regression analyses demonstrated that higher pain scores and medication burdens correlated with elevated standardized measures of impulsivity, clinical depression, generalized anxiety, and emotional aggression. In contrast, total athletic exposure metrics alone did not fully explain the severity of these neuropsychiatric manifestations. Consequently, clinicians evaluating retired contact athletes presenting with explosive anger or depressive episodes should avoid attributing all behavioral instability exclusively to irreversible brain injury. Instead, aggressive management of somatic pain and careful deprescribing of sedating compounds could directly alleviate debilitating affective symptoms.

Differentiating Cognitive Decline from Medication Effects

An intriguing divergence emerged when analyzing cognitive performance across the athletic cohorts. Interestingly, neither centrally acting medications nor chronic pain scores demonstrated a significant association with consensus diagnoses of Traumatic Encephalopathy Syndrome cognitive impairment. This diagnostic stability suggests that the core neurodegenerative amnestic and executive syndromes associated with repetitive head impacts operate independently from somatic pain pathways. Thus, the clinical diagnosis of severe, progressive cognitive impairment reflects localized structural and neuropathological processes.

However, when researchers examined objective cognitive screening using the Montreal Cognitive Assessment, the number of centrally acting medications exhibited a statistically significant negative association. Each additional centrally active drug resulted in an estimated 0.47-point reduction in global cognitive scores. Therefore, while central agents may not induce full diagnostic dementia syndromes, they noticeably suppress processing speed, executive function, and working memory during routine screening. Clinicians must exercise caution when interpreting cognitive tests in polypharmacy patients, as drug-induced mental slowing can readily mask or mimic early neurodegenerative changes.

The Role of Orthopedic History and Surgical Trauma

Retired professional athletes undergo a remarkably high number of surgical procedures to address joint instability, ligamentous tears, and end-stage arthrosis. Within the evaluated sample, professional athletes averaged 2.76 orthopedic operations, collegiate players underwent 1.22, and unexposed controls had only 0.34. Consequently, repeated surgical interventions, perioperative anesthetic exposures, and prolonged rehabilitation cycles represent defining characteristics of post-career athletic life.

Importantly, statistical modeling revealed no direct association between the cumulative number of orthopedic surgeries and subsequent cognitive impairment or neurobehavioral dysregulation. This negative finding is clinically reassuring, as it indicates that structural joint repair and anesthetic history do not drive long-term neuropsychological decline. Instead, the persistent sensory consequence of these injuries—namely chronic nociceptive signaling—and the resulting pharmacotherapy drive behavioral instability. Therefore, surgical management should remain focused on restoring functional mobility, while postoperative care must prioritize non-pharmacological analgesic strategies to prevent secondary central nervous system complications.

Clinical Implications for Multidisciplinary Care

These findings emphasize the urgent necessity of adopting comprehensive multidisciplinary care pathways for former contact sports participants. Because chronic pain and central nervous system medications directly fuel mood disturbance, irritability, and executive slowing, addressing these modifiable factors represents a high-yield therapeutic target. Clinicians should implement structured medication reconciliation protocols, systematically reviewing analgesic regimens to eliminate redundant, sedating, or anticholinergic therapies.

Furthermore, integrating multimodal pain rehabilitation strategies can dramatically reduce reliance on centrally acting pharmaceuticals. Non-pharmacological modalities, including targeted physical therapy, cognitive behavioral therapy for pain, interventional nerve blocks, and mindfulness-based stress reduction, offer proven analgesic efficacy without central neurocognitive suppression. In addition, routine screening for underlying psychiatric comorbidities and sleep apnea provides vital supportive management. By identifying and treating reversible contributors to neurobehavioral distress, healthcare teams can optimize cognitive resilience, improve quality of life, and ensure accurate neurodegenerative disease tracking.

Frequently Asked Questions

How do centrally acting medications affect cognitive screening in former athletes?

Centrally acting medications can induce sedation, reduce mental processing speed, and impair executive performance, leading to measurable drops in Montreal Cognitive Assessment scores without necessarily causing progressive diagnostic dementia syndromes.

Does chronic pain independently increase the risk of neurobehavioral dysregulation?

Yes, higher daily pain scores correlate independently with increased odds of neurobehavioral dysregulation, driving measurable elevations in impulsivity, depressive symptoms, anxiety, emotional lability, and behavioral aggression regardless of total playing exposure.

Do repeated orthopedic surgeries cause long-term neurological or behavioral decline?

No, research demonstrates that cumulative orthopedic surgeries do not independently correlate with neurobehavioral dysregulation or cognitive impairment; instead, chronic post-traumatic pain and subsequent medication regimens drive these behavioral outcomes.

Disclaimer: This content is for informational and educational purposes only and is not intended to serve as medical advice, clinical diagnosis, or treatment guidance. Healthcare professionals should evaluate clinical scenarios independently, integrate findings with comprehensive diagnostic assessments, and tailor interventions to individualized patient needs. Refer to the latest local and national guidelines for clinical practice.

References

1. Puleio A et al. Centrally Acting Medications, Chronic Pain, and Orthopedic Surgical History Among Former American Football Players. Neurology. 2026 Sep 22. doi: 10.1212/WNL.0000000000218475. PMID: 42664488.


2. Katz DI, Bernick C, Dodick DW, et al. National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome. Neurology. 2021;96(18):848-863.


3. Alosco ML, Suire CN, Baucom ZH, et al. Association of Repetitive Head Impacts and Neuropathology With Clinical Traumatic Encephalopathy Syndrome. JAMA Neurol. 2024;81(1):50-61.